Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
Campaign Finance$4,053,880 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Genentech Inc
Names of Lobbyists
Firm Hired Amount Genentech Inc $39,350,968
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Food Industry,
- Science & Technology
Most Frequently Disclosed Bills
Bill No. Title H.R.1548 Pathway for Biosimilars Act H.R.3200 America's Affordable Health Choices Act of 2009 H.R.1 American Recovery and Reinvestment Act of 2009 H.R.1 Full-Year Continuing Appropriations Act, 2011 H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.5629 Pathway for Biosimilars Act H.R.1260 Patent Reform Act of 2009 H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act S.515 Patent Reform Act of 2009 H.R.1908 Patent Reform Act of 2007
Recent Lobbying Contracts
Date Registrant Summary Feb. 17, 2015 Harbinger Strategies, LLC General representation including tax and health care issues. View registration
RegulationsMentioned in 159 dockets; Submitted to 35 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Genentech Inc" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Genentech Inc
- Toggle 26 FDA Proposal to Withdraw Approval; Notice of Opportunity for a Hearing for the Breast Cancer Indication for Bevacizumab (Avastin) 2010
- Toggle 8 FDA Safety Reporting Requirements Human Drug/Biological Products 2000
- Toggle 2 FDA Guidance for Industry on Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices 2008
- Toggle 2 FDA Draft Guidance for Industry and FDA Staff: Applying Human Factors and Usability Engineering to Optimize Medical Device Design; Availability 2011
- Toggle 2 HHS Establishment of Exchanges and Qualified Health Plans 2011
- Toggle 1 FDA Draft Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics 2010
- Toggle 1 FDA Classification of Products as Drugs and Devices & Additional Product Classification Issues; Draft Guidance for Industry and FDA Staff 2011
- Toggle 1 FDA Patent Extension Application for LUCENTIS (ranibizumab), U.S. Patent No. 7,060,269 2007
- Toggle 1 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 1 FDA Draft Guidance for Industry on Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009; Availability 2011
Mentions in Document Text
View all mentions data for Genentech Inc
- Toggle 378 FDA Proposal to Withdraw Approval; Notice of Opportunity for a Hearing for the Breast Cancer Indication for Bevacizumab (Avastin) 2010
- Toggle 15 FDA Require all in Vitro Diagnostic Tests Intended for use in Drug or Biologic Therapeutic Decision Making be Held to the Same Scientific and Regulatory Standards 2008
- Toggle 7 FDA Review safety of Nutropin Depot Injection, issue direction to Genentech Inc. to add warnings regarding diabetes in their safety literature, and consider amending 21 CFR 314.80(e) Postmarketing studies. 2004
- Toggle 6 FDA Patent Extension for AVASTIN (bevacizumab), U.S. Patent No. 6,054,297 2004
- Toggle 4 FDA Guidance for Industry on Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices 2008
- Toggle 4 FDA Patent Extension Application for INCRELEX (mecasermin rDNA orgin injection), U.S. Patent No. 5,681,814 2006
- Toggle 4 FDA Patent Extension Application for LUCENTIS (ranibizumab), U.S. Patent No. 7,060,269 2007
- Toggle 4 FDA Patent Term Extension Application for SOMAVERT (pegvisomant for injection), U.S. Patent No. 5,849,535 2003
- Toggle 3 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
- Toggle 3 FDA Supplements and Other Changes to an Approved Application 2006
Federal Spending3 contracts
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Genentech Incorporated||2005||Veterans Affairs, Department Of||BUYS FOR PHARMACY FCP 560||$2,910,401|
|Genentech Incorporated||2005||Veterans Affairs, Department Of||BUYS FOR PHARMACY FCP 561||$2,310,500|
|Genentech Incorporated||2006||Veterans Affairs, Department Of||ADDITIONAL C NUMBERS FOR APRIL AND MAY 06 ARE C61311,C61362,C61363||$1,207,390|
Advisory Committees6 people on 7 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Genentech Inc" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 5 people on 6 committees
- Toggle National Science Foundation 1 person on 1 committee